IONS
Ionis Pharmaceuticals, Inc.
Stock
$43.54−0.46 (−1.05%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $874M | $944M | $705M | $788M | $587M | $810M | $729M | $1.1B | $600M | $508M | $347M | $284M | $214M | $147M | $102M | $99M | $108M | $122M | $107M |
| Cost of revenue | $16M | $16M | $11M | $9.1M | $14M | $11M | $12M | $4.4M | $1.8M | −$6.5M | −$26M | — | — | — | — | — | — | — | — |
| Gross profit | $858M | $928M | $694M | $779M | $573M | $800M | $717M | $1.1B | $598M | $514M | $373M | — | — | — | — | — | — | — | — |
| R&D | — | $916M | $902M | $900M | — | $638M | $531M | $462M | $412M | $373M | $340M | $320M | $239M | $174M | $155M | $153M | $145M | $135M | $106M |
| SG&A | $528M | $394M | $267M | $233M | $150M | $186M | $354M | $287M | $245M | $108M | $49M | $37M | — | — | — | — | — | — | — |
| Other operating expenses | $925M | — | — | — | $833M | $5.3M | $4.1M | $4.2M | $2.7M | $2.1M | $3.9M | — | — | — | — | — | — | — | — |
| Operating income | −$594M | −$382M | −$475M | −$354M | −$410M | −$30M | −$172M | $366M | −$61M | $31M | −$20M | −$76M | −$48M | −$52M | −$69M | −$71M | −$48M | −$28M | −$13M |
| Non-operating income | $32M | $2.1M | $15M | $20M | $152M | $1.0M | $38M | −$27M | −$15M | −$48M | −$63M | −$12M | −$6.7M | −$15M | −$5.7M | −$14M | −$13M | −$4.2M | — |
| Pretax income | −$562M | −$380M | −$460M | −$334M | −$258M | −$29M | −$135M | $339M | −$76M | −$17M | −$84M | −$88M | −$54M | −$67M | −$75M | −$85M | −$61M | −$32M | — |
| Taxes | $3.2M | $1.8M | −$6.2M | $32M | $12M | −$551K | $310M | $61M | −$350M | −$17M | −$23M | $372K | −$15M | −$5.9M | −$9.1M | $11K | $92K | −$187M | — |
| Net income | −$565M | −$381M | −$454M | −$366M | −$270M | −$29M | −$444M | $278M | $274M | $346K | −$60M | −$88M | −$39M | −$61M | −$65M | −$85M | −$61M | $155M | −$18M |
| Diluted EPS | −$3.70 | −$2.38 | −$3.04 | −$2.56 | −$1.90 | −$0.20 | −$3.18 | $1.90 | $1.66 | $0.12 | −$0.40 | −$1.18 | −$0.53 | −$0.88 | −$1.04 | −$1.36 | −$0.99 | $2.53 | −$0.30 |
| Diluted shares | — | 160.0M | 149.5M | 143.2M | 141.8M | 141.0M | 139.6M | 153.2M | 167.6M | 157.6M | 151.2M | 74.8M | 73.6M | 69.1M | 62.9M | 62.3M | 62.0M | 61.3M | 59.1M |
| Revenue growth | — | +33.8% | −10.5% | +34.1% | −27.5% | +11.1% | −35.0% | +87.2% | +18.1% | +46.5% | +22.2% | +32.5% | +45.4% | +44.3% | +3.0% | −8.7% | −10.8% | +13.4% | — |
| Gross margin | 98.2% | 98.3% | 98.4% | 98.8% | 97.6% | 98.7% | 98.4% | 99.6% | 99.7% | 101.3% | 107.5% | — | — | — | — | — | — | — | — |
| Operating margin | −68.0% | −40.4% | −67.4% | −44.9% | −69.8% | −3.7% | −23.6% | 32.6% | −10.2% | 6.1% | −5.8% | −26.7% | −22.3% | −35.1% | −67.5% | −71.8% | −44.6% | −22.6% | −12.2% |
| Net margin | −64.7% | −40.4% | −64.4% | −46.5% | −45.9% | −3.5% | −60.9% | 24.8% | 45.6% | 0.1% | −17.4% | −31.1% | −18.2% | −41.2% | −64.2% | −85.6% | −56.5% | 127.5% | −17.0% |